Mendota Financial Group LLC Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Mendota Financial Group LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 48.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143 shares of the company’s stock after selling 135 shares during the quarter. Mendota Financial Group LLC’s holdings in Eli Lilly and Company were worth $127,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in LLY. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Eli Lilly and Company by 52.1% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 29,176 shares of the company’s stock worth $25,831,000 after acquiring an additional 9,994 shares in the last quarter. Iowa State Bank grew its holdings in Eli Lilly and Company by 8.9% in the third quarter. Iowa State Bank now owns 5,612 shares of the company’s stock worth $4,972,000 after purchasing an additional 460 shares during the last quarter. Fermata Advisors LLC increased its position in Eli Lilly and Company by 2.3% during the 3rd quarter. Fermata Advisors LLC now owns 1,264 shares of the company’s stock valued at $1,120,000 after buying an additional 29 shares in the last quarter. JGP Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 2.3% during the third quarter. JGP Wealth Management LLC now owns 1,752 shares of the company’s stock valued at $1,552,000 after acquiring an additional 40 shares in the last quarter. Finally, Strong Tower Advisory Services raised its holdings in shares of Eli Lilly and Company by 2.4% in the third quarter. Strong Tower Advisory Services now owns 9,601 shares of the company’s stock worth $8,506,000 after buying an additional 227 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on LLY shares. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Finally, Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $979.29.

Eli Lilly and Company Trading Up 2.3 %

Shares of NYSE:LLY opened at $932.06 on Friday. The business’s 50 day moving average price is $910.84 and its 200-day moving average price is $852.32. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The firm has a market capitalization of $885.83 billion, a price-to-earnings ratio of 137.27, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.